ClinicalTrials.gg
CompletedNCT00693485Updated Apr 24, 2013Results posted

Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy

A Phase 2 interventional study of 400 ug Brimonidine Implant and 200 ug Brimonidine Implant in Glaucoma, Open-Angle, sponsored by Allergan. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-04-24.

Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing brimonidine in Glaucoma, Open-Angle — 1 open to participants now, 1 under way, none of them phase 3. brimonidine · Glaucoma, Open-Angle.

Enrollment
11th of 17
70 · median 120
Started
2008
with 1 other
Phase 2
2 of 18
none open now
Registered
6th of 18
by date
Lead sponsor
6 of 18
Allergan

Among the 18 studies testing brimonidine in Glaucoma, Open-Angle, this one is the 11th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2008, is one of 2 in phase 2, and was the 6th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

1 of the 18 studies testing brimonidine in Glaucoma, Open-Angle is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About brimonidine

brimonidine: first FDA approval 1996 (ALPHAGAN), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing brimonidine in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

A multicenter, randomized, patient-masked, sham-controlled evaluation of the safety and effects on visual function of brimonidine intravitreal implant in patients with glaucomatous optic neuropathy. Patients will be followed for up to 1 year.

03

Conditions studied

  • Glaucoma, Open-Angle

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary open-angle glaucoma in one eye
  • Visual acuity 20/80 or better
  • Intraocular pressure in the study eye ≤ 24 mm Hg
  • Glaucomatous visual field loss - 7 dB to - 25 dB

Exclusion criteria

Exclusion Criteria:

  • Known allergy to brimonidine tartrate
  • Uncontrolled systemic disease or infection of the eye
  • Recent eye surgery or injections in the eye
  • Female patients who are pregnant, nursing or planning a pregnancy
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    400 ug Brimonidine Implant

    400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.

    Drug: 400 ug Brimonidine Implant

  • Experimental
    200 ug Brimonidine Implant

    200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.

    Drug: 200 ug Brimonidine Implant

  • Sham comparator
    Sham (no implant)

    Sham Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.

    Drug: Sham (no implant)

Interventions

  • 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.

    Also known as: Brimonidine Tartrate PS DDS®

  • 200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.

    Also known as: Brimonidine Tartrate PS DDS®

  • DrugSham (no implant)

    Sham Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.

06

What researchers measure

Primary outcomes

  1. Percentage of Patients With a Visual Field Improvement in the Study Eye

    Visual field improvement in the study eye is determined using the Humphrey Field Analyzer (HFA 24-2) full threshold test and clinical expertise. The Humphrey Field Analyzer is a machine that helps to map the field (peripheral) of vision. An improvement is an increase in the field of vision. The percentage of patients with a visual field improvement in the study eye is reported.

    Time frame: Baseline, Month 6

Secondary outcomes

  1. Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye

    BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening.

    Time frame: Baseline, Month 6

07

Results

Posted Apr 24, 2013

Participant flow

Participant flow — Overall Study
Milestone400 ug Brimonidine Implant200 ug Brimonidine ImplantSham (no Implant)
Started252124
Completed251924
Not completed020

Outcome measures

PrimaryPercentage of Patients With a Visual Field Improvement in the Study Eye

Visual field improvement in the study eye is determined using the Humphrey Field Analyzer (HFA 24-2) full threshold test and clinical expertise. The Humphrey Field Analyzer is a machine that helps to map the field (peripheral) of vision. An improvement is an increase in the field of vision. The percentage of patients with a visual field improvement in the study eye is reported.

Time frame:
Baseline, Month 6
Reported as:
Number · Percentage of Patients
Percentage of Patients With a Visual Field Improvement in the Study Eye
Percentage of Patients400 ug Brimonidine Implant200 ug Brimonidine ImplantSham (no Implant)
Percentage of Patients With a Visual Field Improvement in the Study Eye12.09.54.2
SecondaryChange From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye

BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening.

Time frame:
Baseline, Month 6
Reported as:
Mean · Number of Letters Read Correctly
Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye
Number of Letters Read Correctly400 ug Brimonidine Implant200 ug Brimonidine ImplantSham (no Implant)
Baseline76.0 ± 7.8280.6 ± 6.2077.3 ± 7.71
Change from Baseline at Month 62.8 ± 3.68-2.2 ± 18.350.3 ± 5.18

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
400 ug Brimonidine Implant—3/25 (12%)18/25 (72%)
200 ug Brimonidine Implant—5/21 (23.8%)19/21 (90.5%)
Sham (no Implant)—1/24 (4.2%)20/24 (83.3%)
Most frequent serious events
Most frequent serious events
Event400 ug Brimonidine Implant200 ug Brimonidine ImplantSham (no Implant)
Arteriospasm coronaryCardiac disorders0/251/210/24
CataractEye disorders0/251/210/24
ConcussionInjury, poisoning and procedural complications0/251/210/24
ArthritisMusculoskeletal and connective tissue disorders0/251/210/24
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/251/210/24
OsteoarthritisMusculoskeletal and connective tissue disorders0/250/211/24
CellulitisInfections and infestations1/250/210/24
SyncopeNervous system disorders1/250/210/24
HypertensionVascular disorders1/250/210/24
Most frequent other events
Showing 10 of 22
Most frequent other events
Event400 ug Brimonidine Implant200 ug Brimonidine ImplantSham (no Implant)
Conjunctival haemorrhageEye disorders6/252/213/24
Punctate keratitisEye disorders4/252/211/24
HeadacheNervous system disorders4/251/210/24
Conjunctival HyperaemiaEye disorders3/253/213/24
SinusitisInfections and infestations1/252/213/24
CataractEye disorders0/251/213/24
Intraocular pressure increasedInvestigations3/252/212/24
HypertensionVascular disorders3/252/210/24
Eye IrritationEye disorders3/250/212/24
Eye PainEye disorders3/251/210/24

Baseline characteristics

Age, Customized
Age, Customized(Participants)400 ug Brimonidine Implant200 ug Brimonidine ImplantSham (no Implant)Total
<45 years0011
Between 45 and 65 years9111232
>65 years16101137
Sex: Female, Male
Sex: Female, Male(Participants)400 ug Brimonidine Implant200 ug Brimonidine ImplantSham (no Implant)Total
Female12121034
Male1391436
Mean Deviation from Normal Visual Field Using the HFA 24-2
Mean Deviation from Normal Visual Field Using the HFA 24-2(Decibels (db))400 ug Brimonidine Implant200 ug Brimonidine ImplantSham (no Implant)Total
Mean-15.5 ± 5.26-14.6 ± 3.67-17.9 ± 5.09-16.0 (-30.9 to -6.4)
08

Study locations

2 sites
  • Artesia, California, United States
  • Tel Aviv, Israel
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Jan 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2013, 2 years 3 months after primary completion. A results delay was requested in Jan 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2008
First posted
Jun 9, 2008
Start
Sep 2008
Primary completionActual
Jan 2011
CompletionActual
Aug 2011
Results delay requested
Jan 26, 2012
Results first posted
Apr 24, 2013
Last update
Apr 24, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00693485
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Jun 9, 2008
Start date
Sep 2008
Primary completion
Jan 2011
Completion
Aug 2011
Results posted
Apr 24, 2013
Last update
Apr 24, 2013

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion